JP2019514399A5 - - Google Patents

Download PDF

Info

Publication number
JP2019514399A5
JP2019514399A5 JP2018557851A JP2018557851A JP2019514399A5 JP 2019514399 A5 JP2019514399 A5 JP 2019514399A5 JP 2018557851 A JP2018557851 A JP 2018557851A JP 2018557851 A JP2018557851 A JP 2018557851A JP 2019514399 A5 JP2019514399 A5 JP 2019514399A5
Authority
JP
Japan
Prior art keywords
lmm
recombinant polypeptide
cell
nucleic acid
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018557851A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019514399A (ja
JP6959942B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/060484 external-priority patent/WO2017191165A1/en
Publication of JP2019514399A publication Critical patent/JP2019514399A/ja
Publication of JP2019514399A5 publication Critical patent/JP2019514399A5/ja
Application granted granted Critical
Publication of JP6959942B2 publication Critical patent/JP6959942B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018557851A 2016-05-03 2017-05-03 タンパク質生成のための脂質代謝のモジュレーション Active JP6959942B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662330973P 2016-05-03 2016-05-03
US62/330,973 2016-05-03
PCT/EP2017/060484 WO2017191165A1 (en) 2016-05-03 2017-05-03 Modulation of lipid metabolism for protein production

Publications (3)

Publication Number Publication Date
JP2019514399A JP2019514399A (ja) 2019-06-06
JP2019514399A5 true JP2019514399A5 (enExample) 2020-06-18
JP6959942B2 JP6959942B2 (ja) 2021-11-05

Family

ID=58745198

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018557851A Active JP6959942B2 (ja) 2016-05-03 2017-05-03 タンパク質生成のための脂質代謝のモジュレーション

Country Status (13)

Country Link
US (3) US10655111B2 (enExample)
EP (1) EP3452608B1 (enExample)
JP (1) JP6959942B2 (enExample)
KR (1) KR102536221B1 (enExample)
CN (1) CN109415748A (enExample)
AU (1) AU2017259010B2 (enExample)
CA (1) CA3023038C (enExample)
EA (1) EA201892503A1 (enExample)
ES (1) ES2938626T3 (enExample)
IL (2) IL294241B2 (enExample)
MX (1) MX2018013499A (enExample)
SG (1) SG11201809626PA (enExample)
WO (1) WO2017191165A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6959942B2 (ja) 2016-05-03 2021-11-05 ロンザ リミテッドLonza Limited タンパク質生成のための脂質代謝のモジュレーション
WO2020014483A1 (en) * 2018-07-11 2020-01-16 Cornell University Supported plant plasma membrane lipid bilayer on-a-chip
IL280880B2 (en) 2018-08-27 2025-04-01 Regeneron Pharma Using Raman Spectroscopy in Downstream Purification
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
WO2020084528A1 (en) * 2018-10-24 2020-04-30 Selexis Sa Expression systems, recombinant cells and uses thereof
US11504390B2 (en) 2019-03-20 2022-11-22 Regeneron Pharmaceuticals, Inc. Treatment of increased lipid levels with sterol regulatory element binding transcription factor 1 (SREBF1) inhibitors
CN110317799A (zh) * 2019-07-18 2019-10-11 江南大学 一种人源岩藻糖转移酶8的原核表达方法及其产品
KR20220097910A (ko) 2019-11-14 2022-07-08 론자 리미티드 세포 선택 방법
CN115029307A (zh) * 2022-07-28 2022-09-09 吉林大学 一种延缓MSCs衰老的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
EP0985039B1 (en) 1997-06-12 2008-02-20 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
HK1047109A1 (zh) 1999-10-15 2003-02-07 University Of Massachusetts 作为指定基因干预工具的rna干预轨迹基因
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
AU2001275474A1 (en) 2000-06-12 2001-12-24 Akkadix Corporation Materials and methods for the control of nematodes
WO2002095008A2 (en) * 2001-02-02 2002-11-28 Bayer Corporation Methods of modulating surfactant phospholipid production
AU2004248165A1 (en) * 2003-06-11 2004-12-23 Biogen Idec Ma Inc. Method to increase protein production in culture
CN102286483B (zh) 2004-04-16 2014-06-04 中化帝斯曼制药有限公司荷兰公司 用于在真菌细胞中表达基因的真菌启动子
CA2606576A1 (en) * 2005-05-20 2006-11-23 Lonza Biologics Plc. High-level expression of recombinant antibody in a mammalian host cell
US20080182249A1 (en) * 2006-09-01 2008-07-31 Fox Brian G Expression systems for mammalian and mycobacterial desaturases
US20110281301A1 (en) * 2007-11-13 2011-11-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg The secretory capacity in host cells
CA3015426C (en) * 2008-11-18 2020-01-14 Commonwealth Scientific And Industrial Research Organisation Recombinant cells comprising exogenous .delta.5 and .delta.6 desaturases, .delta.5 and .delta.6 elongases, and .delta.4 desaturases
ES2717175T3 (es) * 2013-02-01 2019-06-19 Selexis Sa Expresión mejorada de transgenes y procesamiento
CN105849265B (zh) * 2013-08-06 2021-03-26 英国龙沙生物医药股份有限公司 用于产生供生产重组蛋白的哺乳动物生产细胞的物品和方法
JP6959942B2 (ja) 2016-05-03 2021-11-05 ロンザ リミテッドLonza Limited タンパク質生成のための脂質代謝のモジュレーション

Similar Documents

Publication Publication Date Title
JP2019514399A5 (enExample)
EP4372008A3 (en) Tropism-modified recombinant viral vectors and uses thereof for the targeted introduction of genetic material into human cells
MX2019004499A (es) Sistemas de replicón de virus recombinante y usos de estos.
PH12020551039A1 (en) Non-viral dna vectors and uses thereof for antibody and fusion protein production
SA520411173B1 (ar) Pd-l1 عوامل ربط ترتبط بـ واستخدامها cd137
CY1122195T1 (el) Πολυπεπτιδια συντηξης σερπινης και μεθοδοι χρησης αυτων
PH12019501472A1 (en) Improved methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof
JP2016501829A5 (enExample)
WO2006042158A3 (en) Methods and compositions for improving recombinant protein production
EA201492202A1 (ru) Способ экспрессии гетерологичных белков с использованием рекомбинантного вирусного вектора с минус-нитью рнк
HRP20240408T1 (hr) Inzulin-fc fuzijski proteini ultradugog djelovanja i metode uporabe
ATE481483T1 (de) Verfahren zur herstellung eines rekombinanten polyklonalen proteins
RU2020113032A (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака
WO2014097113A3 (en) Production of therapeutic proteins in genetically modified mammalian cells
EA201190326A8 (ru) Полипептиды гормона роста и способы их получения и применения
AR080942A1 (es) Produccion de proteinas heteromultimericas
MX2012005864A (es) Proteinas de enlace al antígeno anti-orai 1 y usos de las mismas.
IN2015DN01115A (enExample)
WO2012009544A3 (en) Domain insertion immunoglobulin
EP4286522A3 (en) Fusion proteins of pd-1 and 4-1bb
WO2010018444A3 (en) An expression vector and a method thereof
CN107058235B (zh) 一种b细胞筛选方法及其在单克隆抗体制备中的应用
BR112017027702A2 (pt) anticorpos antirreceptor do fator de crescimento endotelial vascular 2 (vegfr2)
CN104350068B (zh) 生产型细胞系的增强子
PH12021552833A1 (en) Variant domains for multimerizing proteins and separation thereof